Business Network New York
Companies:51,220
Products and Services:2,873
Articles and publications:31,070 (+1)
Tenders & Vacancies:17

GenieUs and Perron Institute move into exciting next phase of RNA drug development
Information may not be reliable

11/29/2021
These are encouraging early findings and we hope that we will be able to collect enough evidence to be able to move into clinical trials in the very near future. ”

Sydney, Australia, Perth, Western Australia, TBC November 2021: GenieUs Pty Ltd, a genomics discovery company that uses data analytics and machine learning to better understand the cause of neurodegenerative diseases, and the Perron Institute, Perth who develop RNA therapies called Antisense Oligonucleotides have developed two unique candidate therapeutics that could ultimately translate into treatment options for patients suffering from neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), and Parkinson’s Disease.

Using a genomic medicine approach, the latest data from patients cells has shown that two microRNA therapies have strong target engagement and can potentially regulate genes known to affect ALS (the most common form of MND) and Parkinson’s. MicroRNA are small molecules that regulate genes by “RNA silencing” a process that neurons and other cells in the body use to regulate the amount of proteins required for biological processes like growth and repair. Micro RNA can regulate a number of genes at once and this is why GenieUs has focused on this RNA based cell process, to identify novel therapeutic candidates.

 

The GenieUs team uncovered a number of microRNA targets that were significantly dysregulated in motor neurons from MND/ALS patients using a comprehensive genomic medicine-based approach which included the spinal fluid from ALS patients. GenieUs and the Perron Institute have partnered to develop an antisense technology approach to directly target the dysregulated microRNA. In an exciting partnership with the MND research group at the Perron Institute, the two teams have been keenly working to evaluate these microRNA targets leveraging the Perron Institute MND research group’s extensive track record in gene targeting antisense therapeutics for ALS/MND and other neurological conditions. The Perron institute MND research team, specialises in the development and translation of antisense therapeutics for patients, and has a number of candidate medicines in various stages of preclinical testing in preparation for first time in human studies.

 

Dr Loren Flynn (Perron institute postdoctoral research fellow), who is an inventor of several MND antisense therapeutics and Dr Sam Brennan (GenieUs) have reviewed the preliminary data showing the potential for regulating these novel MND related microRNAs and selected two primary candidate targets to move forward in the coming 12 months.

 

The Joint team of Matt Keon, GenieUs CEO, and Professor Anthony Akkari, head of the MND genetics and therapeutics group at the Perron Institute, will test RNA therapies in patient stem cells models over the next 12 months to show efficacy.

 

Founded in 2017, GenieUs’ analytics solution is at the forefront of bioanalytical analysis of datasets to map and sub-categorise neurodegenerative diseases for more personalised treatment options.  Neurodegenerative diseases are complex and vary between people, so it is important to understand  the unique genetic backgrounds and molecular events that cause the condition and create truly personalised care and treatment for people.The Perron Institute, established in 1982 is the longest established medical research institute in Western Australia and is researching a range of neurological disorders. It brings together a dedicated range of researchers and clinicians, many pre-eminent in their fields. The Perron Institute has contributed to a number of neuromuscular disease discoveries over the years, this includes the SOD1 gene the first gene discovered for MND back in 1992, and most recently the first antisense therapeutics for Duchenne muscular dystrophy.

This advance is a further step towards unravelling one of the greatest health challenges we face; enabling earlier intervention to facilitate improved clinical outcomes for patients. 

Matt Keon, CEO and co-founder of GenieUs, said: “As with everything we do, we seek to provide therapies safely and quickly to patients. These are encouraging early findings and we hope that we will be able to collect enough evidence to be able to move into clinical trials in the very near future.”

Professor Anthony Akkari, Head of Motor Neurone Disease Genetics and Therapeutics Research at the Perron Institute said: “It is our goal to provide new treatment options for people living with these devastating conditions as quickly as possible.”

GenieUs has been awarded a patent for the biomarker of one the microRNA’s they are developing.   

-ENDS-

About GenieUs

GenieUs is a science and technology company using  a proprietary model of data analytics and machine learning to solve the mystery of neurodegenerative diseases, one of the most misunderstood condition areas on the planet. Founded in 2017, its analytics solution uses in-house algorithms and the deepest integration of datasets to map and sub-categorise neurodegenerative diseases for more personalised treatment.

About Perron Institute

For over 39 years, the Perron Institute has continued to build its reputation as an innovative medical research institute which has made significant breakthroughs across a broad spectrum of neurological conditions. Perron Institute’s multidisciplinary approach enables the translation of research outcomes into treatments aimed at providing a better quality of life for millions of people around the world who suffer with devastating neurological conditions.

About Neurodegenerative Disease

Neurodegenerative diseases like motor neuron diseases and dementia are one of our fastest-growing health risks. There are 10 million new cases of dementia globally every year, yet research and diagnosis are years behind diseases like cancer.

###

 

view all (2604)

Other articles and publications:

Eat This! has leveraged its flexibility and adaptability to tap into current trends and preferences, allowing it.
8/15/2023
A backpack makes your journey hassle-free and you may move about together with your toddler comfortably.
10/25/2018
Reasonably priced Types of Dinnerware Sets
Information may not be reliable
Porcelain can be a product made of kaolin clay surfaces and fine quartz. Dinnerware Sets is used burly in chip-restaurants and is easily contoured into delicate forms.
5/19/2020
This award-winning film is a wonderful addition to our line-up, and we look forward to working with Bhushan and his team well into the future.
4/22/2021
Alterola Biotech Inc. Acquires Abti Pharma Ltd
Information may not be reliable
Alterola Biotech Inc. acquires ABTI Pharma Ltd as part of its strategic move into the cannabinoid medicines sector.
7/22/2021
Award-Winning Entrepreneur and Business Growth Expert – Ursula Mentjes Is Set To Provide Assistance with Her Scale 2-7 Formula Course To CEOs Interested In Exceeding Their Annual Revenue By 2X-10X
6/24/2022

Articles and publications of other companies:

United Moving Spaces is a fast growing and reputed moving service provider in the US holding US Department of Transportation license.
5/24/2019
Vancouver’s best commercial and residential cleaning services company EcoGREEN Cleaning has launched a new website and online booking platform to serve its customers better. .
6/6/2019
The TKX brand electrical chain hoist, manual hoist and other lifting machines manufactured by Chinese company Jiali Machinery Co., Ltd
6/8/2019
Specialized in manufacturing LED flashlights and rechargeable flashlight, tactical flashlight, etc., Tank007 Lighting INC. has become the most reliable and recognized LED flashlight manufacturer.
1/4/2019
Now you don't have to face any problem with the liver. Here the bodydetox101 has announced exciting liver cleanse program and body detox advice what will keep your liver healthy.
6/16/2019
The Sanders Hand is a non-profit charity helping youth across Texas and Oklahoma. Its dynamic founder is revealing the power of community service
4/2/2020
Business details
  • +1 (516) 547-0884
  • USA
I am 5 years experience of seo in digital marketing
×